Compare TMDX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | MIRM |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | 2019 | 2019 |
| Metric | TMDX | MIRM |
|---|---|---|
| Price | $123.69 | $78.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $144.25 | $92.45 |
| AVG Volume (30 Days) | 724.8K | ★ 813.7K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $566,354,000.00 | $471,794,000.00 |
| Revenue This Year | $38.81 | $53.78 |
| Revenue Next Year | $20.49 | $19.91 |
| P/E Ratio | $48.97 | ★ N/A |
| Revenue Growth | 41.20 | ★ 53.66 |
| 52 Week Low | $55.00 | $36.88 |
| 52 Week High | $156.00 | $82.58 |
| Indicator | TMDX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 62.89 |
| Support Level | $120.82 | $63.23 |
| Resistance Level | $133.29 | $82.58 |
| Average True Range (ATR) | 5.52 | 3.74 |
| MACD | -0.91 | 1.62 |
| Stochastic Oscillator | 19.55 | 81.03 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.